肝硬化低蛋白症的治疗(国产马洛替酯实验研究)

Treatment of Hypoproteinemia in Liver Cirrhosis A Pharmacodynamic Research on Malotilate

肝硬化肝脏的蛋白质功能低下引起的低蛋白症,单纯采用高蛋白饮食或输注白蛋白制剂常不能得到满意解决。实验证实国产马洛替酯对CCl_4急性肝损害家兔,可促进其凝血因子合成;对CCl_4慢性肝损害大鼠,有明显的抑制肝细胞脂肪变性和纤维化形成的作用,从而避免发生肝硬化。该药的合成和研制为治疗肝硬化及其低蛋白症提供了一个新的途径。

This is a basic pharmacodynamic research on the home products of Malotilate. The authors demonstrate tha.t Malotilate can stimulate the synthesis of coagulating factors in rabbits suffering from acute hepatotoxicity due to earbontetrachloride (CCl_4), and also inhibit fatty degeneration and fibrosis in rats with chronic hepatotoxicity caused by CGl_4. On the basis of these facts and pathophysiological changes during the formation of hypoproteinemia in liver cirrhosis the implication of Malotilate therapy and other treatment is discussed and evaluated.